In our rat AD model, we found that the p-GSK-3β (Ser9) level was decreased (i.e., increased GSK-3β activity) with a subsequent decrease in the total hippocampal β-catenin and BDNF levels. This evidence concerns the gene GSK3B and Alzheimer disease.